Chest
Original ResearchCystic FibrosisInhaled Mannitol Improves the Hydration and Surface Properties of Sputum in Patients With Cystic Fibrosis
Section snippets
Subjects
Thirty-nine subjects with CF, clinically stable, from Australia and New Zealand were randomized, and 35 subjects completed both treatments of the study.7 Subjects were > 8 years old and had FEV1 between 41% and 91% predicted. Eligible subjects were premedicated with 400 μg of salbutamol prior to having an airway challenge with mannitol (Aridol; Pharmaxis Ltd; Frenchs Forest, NSW, Australia) following a standard protocol8 to exclude subjects with airway hyperresponsiveness to mannitol. Subjects
Results
There was no significant difference in the sputum properties between mannitol and placebo treatment at baseline and after a 2-week washout period. In addition, the order of treatment did not influence any of the sputum properties (ie, there was no carryover effect).
The solids content and surface properties of sputum were significantly reduced after a 2-week treatment with mannitol inhaled bid in patients with CF. This reduction was observed approximately 12 h after the last dose. The reduction
Discussion
Treatment with inhaled mannitol over 2 weeks improved the hydration and surface properties of sputum in patients with CF. The effect of mannitol on the sputum properties was evident for approximately 12 h after the end of the last treatment dose. This is the first in vivo study to show a sustained effect of mannitol on the sputum properties in CF. In addition, the reduction in solids content and surface properties correlated with the improvement in the lung function in these patients after 2
Acknowledgments
Author contributions: Dr Daviskas: contributed to the study design, measurement and analysis of sputum properties, interpretation of the findings, and writing the manuscript.
Dr Anderson: contributed to the study design, interpretation of the findings, and writing the manuscript.
Ms Jaques: contributed to the study design, interpretation of the findings, and writing the manuscript.
Dr Charlton: contributed to the study design, interpretation of the findings, and writing the manuscript.
References (0)
Cited by (76)
Mucoactive drugs and multiple applications in pulmonary disease therapy
2024, European Journal of Pharmaceutics and BiopharmaceuticsA review of upper airway physiology relevant to the delivery and deposition of inhalation aerosols
2022, Advanced Drug Delivery ReviewsMucus-targeting therapies of defective mucus clearance for cystic fibrosis: A short review
2022, Current Opinion in PharmacologyEfficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study
2021, Journal of Cystic FibrosisCitation Excerpt :Since administration time and medication number impact adherence, decreasing perceived treatment burden is critical when developing add-on therapies for CF. [11] Mannitol is a mucoactive hyperosmotic agent that hydrates the airway surface liquid, thereby changing mucus viscoelastic properties, and increasing mucociliary and cough mucus clearance. [14,15] It is administered twice-daily (BID) via a small, portable breath-actuated dry-powder inhaler, and is used as add-on to standard of care, including dornase alfa and inhaled antibiotics, to improve lung function in adults with CF. The portability and short administration time (approximately 5 min in clinical studies [16-18]) of this drug-device combination may translate into reduced treatment burden, potentially improving adherence to mucolytics.
Inhalation delivery technology for genome-editing of respiratory diseases
2021, Advanced Drug Delivery ReviewsDelivery of genome-editing biomacromolecules for treatment of lung genetic disorders
2021, Advanced Drug Delivery ReviewsCitation Excerpt :Mucus-altering agents, such as recombinant human DNase and N-acetyl cysteine, can enlarge mucus mesh pore size to facilitate the penetration of gene vectors through airway mucus [168,169]. Furthermore, some osmotic agents, such as hypertonic saline and mannitol, can be incorporated into inhaled formulation to increase mucus and/or PCL mesh pore size by hydration as well as to enhance mucociliary clearance [170,171]. In addition, tight-junction disrupting agents (such as sodium caprate, polidocanol, and lysophosphatidylcholine) which transiently disrupt tight junctions in the epithelial layer, help gene vectors to access the basolateral surface [11,172,173].
Funding/Support: This study was sponsored by Pharmaxis Ltd.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestpubs.org/site/misc/reprints.xhtml).